▲ +400.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Diffusion Pharmaceuticals in the last 3 months. The average price target is $3.50, with a high forecast of $3.50 and a low forecast of $3.50. The average price target represents a 400.00% upside from the last price of $0.70.
The current consensus among 1 investment analysts is to hold stock in Diffusion Pharmaceuticals. This Hold consensus rating has held steady for over two years.
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.